Applied Therapeutics Inc (NASDAQ:APLT) — Market Cap & Net Worth
Market Cap & Net Worth: Applied Therapeutics Inc (APLT)
Applied Therapeutics Inc (NASDAQ:APLT) has a market capitalization of $14.86 Million ($14.86 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26108 globally and #5462 in its home market, demonstrating a 6.96% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Applied Therapeutics Inc's stock price $0.10 by its total outstanding shares 144300674 (144.30 Million). Also see Applied Therapeutics Inc balance sheet assets for a full breakdown of the balance sheet.
Applied Therapeutics Inc Market Cap History: 2019 to 2026
Applied Therapeutics Inc's market capitalization history from 2019 to 2026. Data shows change from $3.94 Billion to $14.86 Million (-48.84% CAGR). Also see Applied Therapeutics Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Applied Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #738 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2414 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.00% | #251 of 263 |
Weight: Applied Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Applied Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Applied Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Applied Therapeutics Inc (APLT) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
271.54x
Applied Therapeutics Inc's market cap is 271.54 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $109.67 Million | $10.66 Million | -$82.51 Million | 10.29x | N/A |
| 2023 | $483.41 Million | $9.99 Million | -$119.76 Million | 48.37x | N/A |
| 2024 | $123.55 Million | $455.00K | -$105.62 Million | 271.54x | N/A |
Competitor Companies of APLT by Market Capitalization
Companies near Applied Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review Applied Therapeutics Inc (APLT) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Applied Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Applied Therapeutics Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Applied Therapeutics Inc's market cap moved from $3.94 Billion to $ 14.86 Million, with a yearly change of -48.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $14.86 Million | +3.00% |
| 2025 | $14.43 Million | -88.32% |
| 2024 | $123.55 Million | -74.44% |
| 2023 | $483.41 Million | +340.79% |
| 2022 | $109.67 Million | -91.51% |
| 2021 | $1.29 Billion | -59.34% |
| 2020 | $3.18 Billion | -19.32% |
| 2019 | $3.94 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Applied Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.86 Million USD |
| MoneyControl | $14.86 Million USD |
| MarketWatch | $14.86 Million USD |
| marketcap.company | $14.86 Million USD |
| Reuters | $14.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Applied Therapeutics Inc
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric cli… Read more